Schistosomiasis: From risk assessment to control

Trends in Parasitology

Volumn 18, Issue 7, 2002, Pages 309-314

  Bergquist, Nils Robert ^a  

^a WORLD BANK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISCHISTOSOMAL AGENT; ARTEMISININ DERIVATIVE; EOSINOPHIL CATIONIC PROTEIN; FATTY ACID BINDING PROTEIN; GLUTATHIONE TRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; METRIFONATE; MONOCLONAL ANTIBODY; OXAMNIQUINE; PARAMYOSIN; PARASITE ANTIGEN; PRAZIQUANTEL; SCHISTOSOMA VACCINE; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG; VACCINE ANTIGEN 5;

CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFECT; DRUG HALF LIFE; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHIC INFORMATION SYSTEM; HIGH RISK POPULATION; HUMAN; INFECTION RISK; LIVER FIBROSIS; MALARIA; MORBIDITY; MORTALITY; NON INVASIVE MEASUREMENT; NONHUMAN; PARASITE IDENTIFICATION; PARASITE IMMUNITY; PREDICTION; PREVALENCE; QUESTIONNAIRE; REMOTE SENSING; REVIEW; RISK ASSESSMENT; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SPECIES DIFFERENCE; TREATMENT OUTCOME; ULTRASOUND; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANIMALS; ANTHELMINTICS; ENDEMIC DISEASES; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MALE; MIDDLE AGED; PRAZIQUANTEL; PREVALENCE; PUBLIC HEALTH; SCHISTOSOMA; SCHISTOSOMIASIS;

SCHISTOSOMA; SCHISTOSOMA MANSONI; TREMATODA;

EID: 0036630087     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4922(02)02301-2     Document Type: Review

References (62)

1. st Century. Science. 293:2001;1437-1438.
2. van der Werf, M.J. et al. Quantification of clinical morbidity associated with schistosome infection in subSaharan Africa. Acta Trop. (in press)
3. Chitsulo L., et al. The global status of schistosomiasis and its control. Acta Trop. 77:2000;41-51.
4. Prevention and Control of Schistosomiasis and Soil-transmitted Helminthiasis First Report of the Joint Expert Committees WHO (in press)
5. Giboda M., Bergquist N.R. Post-transmission schistosomiasis: a new agenda. Acta Trop. 77:2000;3-7.
6. Hunter, J.M. et al. (eds) (1993) Parasitic Diseases in Water Resources Development. The Need for Intersectoral Negotiation, p. 152, World Health Organization
7. van Lieshut L., et al. Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections. Acta Trop. 77:2000;69-80.
8. Guanling, W.U. A historical perspective in immunodiagnosis of schistosomiasis in China. Acta Trop. (in press)
9. Bergquist N.R. Immunodiagnostic approaches in schistosomiasis. Immunodiagnostics of Schistosomiasis. 1990;1-8 John Wiley & Sons.
10. Leutscher P.D., et al. Morbidity assessment in urinary schistosomiasis infection through ultrasonography and measurement of eosinophil cationic protein (ECP) in urine. Trop. Med. Int. Health. 5:2000;88-93.
11. Jyding-Vennervald B., et al. Assessment of morbidity in Schistosoma haematobium infection: current methods and future tools. Acta Trop. 77:2000;81-89.
12. Jenkins, J.M. et al. (1990) The Use of Ultrasound in Schistosomiasis: Proposal for a Practical Guide to the Standardized Use of Ultrasound in the Assessment of Pathological Changes. TDR/SCH/ULTRASON/91.3
13. Richter, J. et al. (2000) Ultrasound in Schistosomiasis: A Practical Guide to the Standardized Use of Ultrasonography for Assessment of Schistosomiasis-related Morbidity. Workshop Report TDR/STR/SCH/00.1. WHO
14. Richter J. Report of the second satellite symposium on ultrasound in schistosomiasis. Mem. Inst. Oswaldo Cruz. 96:(Suppl.):2001;151-156.
15. Hatz C.F., et al. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am. J. Trop. Med. Hyg. 59:1998;775-781.
16. Richter J. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop. 77:2000;111-131.
17. Homeida M.M., et al. The effectiveness of annual versus biennial mass chemotherapy in reducing morbidity due to schistosomiasis: a prospective study in Gezira-Managil, Sudan. Am. J. Trop. Med. Hyg. 54:1996;140-145.
18. Ohmae H., et al. Improvement of ultrasonographic and serologic changes in Schistosoma japonicum-infected patients after treatment with praziquantel. Am. J. Trop. Med. Hyg. 46:1992;99-104.
19. Thomson M., et al. Environmental information for prediction of epidemics. Parasitol. Today. 16:2000;137-138.
20. Brooker S., et al. Towards an atlas of human helminth infection in sub-Saharan Africa: the use of Geographical Information Systems (GIS). Parasitol. Today. 16:2000;303-307.
21. Brooker S., et al. The potential of rapid screening methods for Schistosoma mansoni in western Kenya. Ann. Trop. Med. Parasitol. 95:2001;343-351.
22. Kitron U. Risk maps: transmission and burden of vector-borne diseases. Parasitol. Today. 16:2000;324-325.
23. Savioli L., Mott K.E. Urinary schistosomiasis on Pemba Island: low-cost diagnosis for control in a primary health care setting. Parasitol. Today. 5:1989;333-337.
24. Identification of High-Risk Communities for Schistosomiasis in Africa: A Multicountry Study. Produced by the 'Red Urine Study Group' as final report in the TDR Social and Economic Research Series, 83 pp. TDR/SER/PRS/15, World Health Organization, 1995
25. Lengeler C.h., et al. Questionnaires for rapid screening of schistosomiasis in sub-Saharan Africa. Bull. WHO. 80:2002;235-242.
26. Chitsulo L. et al. (2002) The Schistosomiasis Manual. Methods for Social Research in Tropical Diseases No. 3, 30 pp. 30TDR/SER/MSR/.2.
27. Lengeler C., et al. Simple school questionnaires can map both Schistosoma mansoni and Schistosoma haematobium in the Democratic Republic of Congo. Acta Trop. 74:2000;77-87.
28. Utzinger J., et al. Rapid screening for Schistosoma mansoni in western Côte d'Ivoire using a simple school questionnaire. Bull. WHO. 78:2000;389-398.
29. Zhou H., et al. Diagnosis of schistosomiasis japonica in Chinese schoolchildren by administration of a questionnaire. Trans. R. Soc. Trop. Med. Hyg. 92:1998;245-250.
30. Bergquist N.R. Vector-borne diseases: new trends in data collection and risk assessment. Acta Trop. 79:2001;13-20.
31. Malone J.B., et al. A global network for the control of snail-borne disease using satellite surveillance and geographic information systems. Acta Trop. 79:2001;7-12.
32. Huh O.K., Malone J.B. New tools: potential medical applications of data from new and old environmental satellites. Acta Trop. 79:2001;35-47.
33. Bernardi M. Linkages between FAO agroclimatic data resources and the development of GIS models for control of vector-borne diseases. Acta Trop. 79:2001;21-34.
34. WHO . Geographical Information Systems (GIS) - Mapping for epidemiological surveillance. Wkly Epidemiol. Rec. 74:1999;281-288.
35. Malone J.B., et al. Satellite climatology and the environmental risk of Schistosoma mansoni in Ethiopia and East Africa. Acta Trop. 79:2001;59-72.
36. Poggensee G., Feldmeier H. Female genital schistosomiasis: facts and hypotheses. Acta Trop. 79:2001;193-210.
37. Leutscher P., et al. Clinical findings in female genital schistosomiasis in Madagascar. Trop. Med. Int. Health. 3:1998;327-332.
38. Qunhua L., et al. Investigation of association between female genital tract diseases and schistosomiasis japonica infection. Acta Trop. 77:2000;179-183.
39. Leutscher P., et al. Community-based study of genital schistosomiasis in men from Madagascar. Lancet. 355:2000;117-118.
40. Gryseels B., et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med. Int. Health. 6:2001;864-873.
41. Doenhoff M., et al. Praziquantel and the control of schistosomiasis. Parasitol. Today. 16:2000;364-366.
42. Utzinger J., et al. The potential of artemether for the control of schistosomiasis. Int. J. Parasitol. 31:2001;1549-1562.
43. Xiao S.H., et al. The prophylactic effects of artemether against Schistosoma japonicum infections. Parasitol. Today. 16:2000;122-126.
44. Chen D.J., et al. Effect of artemisinin on experimental animals infected with Schistosoma japonicum. Chin. Med. J. 80:1980;422-425.
45. Yuan H.C., et al. The 1992-1999 World Bank schistosomiasis research initiative in China: outcome and perspectives. Parasitol. Int. 49:2000;195-207.
46. Utzinger, J. et al. Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. Trans. R. Soc. Trop. Med. Hyg. (in press)
47. White N. Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:1999;739-749.
48. Xiao, S.H. et al. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop. (in press)
49. Stadecker M.J. The development of granulomas in schistosomiasis: genetic backgrounds, regulatory pathways, and specific egg antigen responses that influence the magnitude of disease. Microbes Infect. 1:1999;505-510.
50. Rutitzky L.I., et al. Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13243-13248.
51. Hernandez H.J., et al. Experimental murine schistosomiasis in the absence of B7 costimulatory molecules: reversal of elicited T cell cytokine profile and partial inhibition of egg granuloma formation. J. Immunol. 62:1999;2884-2889.
52. Bergquist R. Controlling schistosomiasis by vaccination: a realistic option? Parasitol. Today. 11:1995;191-194.
53. Capron A., et al. Vaccine strategies against schistosomiasis: from concepts to clinical trials. Int. Arch. Allergy Immunol. 124:2001;9-15.
54. Pearce E.J., et al. Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5678-5682.
55. Tendler M., et al. A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. Proc. Natl. Acad. Sci. U. S. A. 93:1996;269-273.
56. Harn D.A., et al. Synthetic peptide vaccines for schistosomiasis. Pharm. Biotechnol. 6:1995;891-905.
57. Soisson L.M., et al. Induction of protective immunity in mice using a 62-kDa recombinant fragment of a Schistosoma mansoni surface antigen. J. Immunol. 149:1992;3612-3620.
58. Goudot-Crozel V. The major parasite surface antigen associated with human resistance to schistosomiasis is a 37-kD glyceraldehyde-3P-dehydrogenase. J. Exp. Med. 170:1989;2065-2080.
59. Argiro L., et al. Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum. Vaccine. 17:1999;13-18.
60. MacManus D.P., et al. Recombinant paramyosin (rec-Sj-97) tested for immunogenicity and vaccine efficacy against Schistosoma japonicum in mice and water buffaloes. Vaccine. 20:2001;870-878.
61. Johansen M.V., et al. Schistosoma japonicum infection in the pig as a model for human schistosomiasis japonica. Acta Trop. 76:2000;85-99.
62. Ribeiro de Jesus A., et al. Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect. Immun. 68:2000;2797-2803.